Entrada Therapeutics’ (TRDA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2025 earnings at ($0.98) EPS, Q3 2025 earnings at […]
HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2025 earnings at ($0.98) EPS, Q3 2025 earnings at […]
